IL6 and atherosclerosis: Despite significant advancements in understanding the pathophysiology of atherosclerosis, the role of TCAs as anti-inflammatory agents remains inadequately explored, with conflicting findings regarding their effects on inflammatory pathways such as IL-6 and TNF-α.